266 related articles for article (PubMed ID: 38540782)
21. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
22. Detection of Circulating Tumor Cells Using Negative Enrichment Immunofluorescence and an In Situ Hybridization System in Pancreatic Cancer.
Xu Y; Qin T; Li J; Wang X; Gao C; Xu C; Hao J; Liu J; Gao S; Ren H
Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28333072
[TBL] [Abstract][Full Text] [Related]
23. Biomarkers for early detection of pancreatic cancer - miRNAs as a potential diagnostic and therapeutic tool?
Tarasiuk A; Mackiewicz T; Małecka-Panas E; Fichna J
Cancer Biol Ther; 2021 Jun; 22(5-6):347-356. PubMed ID: 34224317
[TBL] [Abstract][Full Text] [Related]
24. Advances in Liquid Biopsy Technology and Implications for Pancreatic Cancer.
Raufi AG; May MS; Hadfield MJ; Seyhan AA; El-Deiry WS
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835649
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic biomarkers for pancreatic cancer: An update.
Yang M; Zhang CY
World J Gastroenterol; 2021 Dec; 27(45):7862-7865. PubMed ID: 34963749
[TBL] [Abstract][Full Text] [Related]
26. Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer.
Rachagani S; Macha MA; Heimann N; Seshacharyulu P; Haridas D; Chugh S; Batra SK
Adv Drug Deliv Rev; 2015 Jan; 81():16-33. PubMed ID: 25453266
[TBL] [Abstract][Full Text] [Related]
27. Liquid biopsy leads to a paradigm shift in the treatment of pancreatic cancer.
Watanabe F; Suzuki K; Noda H; Rikiyama T
World J Gastroenterol; 2022 Dec; 28(46):6478-6496. PubMed ID: 36569270
[TBL] [Abstract][Full Text] [Related]
28. Liquid biopsy = Individualized cancer management: Diagnosis, monitoring treatment and checking recurrence and metastasis.
Mali SB; Dahivelkar S
Oral Oncol; 2021 Dec; 123():105588. PubMed ID: 34744021
[TBL] [Abstract][Full Text] [Related]
29. Liquid Biopsy in Head and Neck Cancer: Promises and Challenges.
Nonaka T; Wong DTW
J Dent Res; 2018 Jun; 97(6):701-708. PubMed ID: 29513618
[TBL] [Abstract][Full Text] [Related]
30. Liquid biopsy in ovarian cancer: the potential of circulating miRNAs and exosomes.
Giannopoulou L; Zavridou M; Kasimir-Bauer S; Lianidou ES
Transl Res; 2019 Mar; 205():77-91. PubMed ID: 30391474
[TBL] [Abstract][Full Text] [Related]
31. Applications of Liquid Biopsy for Surgical Patients With Cancer: A Review.
Mahuron KM; Fong Y
JAMA Surg; 2024 Jan; 159(1):96-103. PubMed ID: 37910091
[TBL] [Abstract][Full Text] [Related]
32. A clinical study of serum human epididymis protein 4 (HE4) in the diagnosis of pancreatic cancer.
Liu W; Liu W; Lin K; Liu Y; Hu H; Yang L
Indian J Cancer; 2022; 59(2):223-229. PubMed ID: 34380855
[TBL] [Abstract][Full Text] [Related]
33. Improving pancreatic cancer diagnosis using circulating tumor cells: prospects for staging and single-cell analysis.
Court CM; Ankeny JS; Hou S; Tseng HR; Tomlinson JS
Expert Rev Mol Diagn; 2015; 15(11):1491-504. PubMed ID: 26390158
[TBL] [Abstract][Full Text] [Related]
34. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.
Pereira E; Camacho-Vanegas O; Anand S; Sebra R; Catalina Camacho S; Garnar-Wortzel L; Nair N; Moshier E; Wooten M; Uzilov A; Chen R; Prasad-Hayes M; Zakashansky K; Beddoe AM; Schadt E; Dottino P; Martignetti JA
PLoS One; 2015; 10(12):e0145754. PubMed ID: 26717006
[TBL] [Abstract][Full Text] [Related]
35. Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer.
Kaur S; Chakraborty S; Baine MJ; Mallya K; Smith LM; Sasson A; Brand R; Guha S; Jain M; Wittel U; Singh SK; Batra SK
PLoS One; 2013; 8(2):e55171. PubMed ID: 23383312
[TBL] [Abstract][Full Text] [Related]
36. Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer.
Dittmar RL; Liu S; Tai MC; Rajapakshe K; Huang Y; Longton G; DeCapite C; Hurd MW; Paris PL; Kirkwood KS; Coarfa C; Maitra A; Brand RE; Killary AM; Sen S
Cancer Prev Res (Phila); 2021 Jul; 14(7):729-740. PubMed ID: 33893071
[TBL] [Abstract][Full Text] [Related]
37. Longitudinal Study of Circulating Biomarkers in Patients with Resectable Pancreatic Ductal Adenocarcinoma.
Dopico PJ; Le MN; Burgess B; Yang Z; Zhao Y; Wang Y; George TJ; Fan ZH
Biosensors (Basel); 2022 Mar; 12(4):. PubMed ID: 35448266
[TBL] [Abstract][Full Text] [Related]
38. Identification of Circulating Serum miRNAs as Novel Biomarkers in Pancreatic Cancer Using a Penalized Algorithm.
Lee J; Lee HS; Park SB; Kim C; Kim K; Jung DE; Song SY
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33498271
[TBL] [Abstract][Full Text] [Related]
39. Metastatic pancreatic cancer: Mechanisms and detection (Review).
Chen X; Liu F; Xue Q; Weng X; Xu F
Oncol Rep; 2021 Nov; 46(5):. PubMed ID: 34498718
[TBL] [Abstract][Full Text] [Related]
40. [Clinical Application of Liquid Biopsy for Breast Cancer Diagnosis and Treatment].
Shimomura A; Ochiya T
Gan To Kagaku Ryoho; 2021 Oct; 48(10):1197-1202. PubMed ID: 34657047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
